Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) yesterday and set a ...

Florida health officials are raising alarms about the safety of the newest versions of mRNA COVID-19 vaccines, advising ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use..." ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...

THE LAWSUIT: A class action securities lawsuit was filed against Moderna, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between January 18, ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.

Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

A German study published in July 2024 did not find that mRNA COVID-19 vaccines damaged children’s immune systems, contrary to ...

We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks. In this article, we are going to take a look at ...

Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 ...